Lantern Pharma (LTRN) announced that the European Patent Office has issued a notice of allowance for a composition of matter patent covering its drug candidate LP-284. This patent is expected to be granted in the coming months with exclusivity through early 2039.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LTRN: